Advertisement
Letter to the Editor| Volume 65, ISSUE 6, P1267-1268, December 2016

Download started.

Ok

Reply to “Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease”

  • Raluca Pais
    Correspondence
    Corresponding author. Address: Service Hépatogastroentérologie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpétrière – Université Pierre et Marie Curie, UMR_S 938, INSERM – CDR Saint Antoine, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France. Tel.: +33 674824522.
    Affiliations
    Service Hépatogastroentérologie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpétrière – Université Pierre et Marie Curie, UMR_S 938, INSERM – CDR Saint Antoine, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
    Search for articles by this author
  • Vlad Ratziu
    Affiliations
    Service Hépatogastroentérologie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpétrière – Université Pierre et Marie Curie, UMR_S 938, INSERM – CDR Saint Antoine, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
    Search for articles by this author
Published:August 04, 2016DOI:https://doi.org/10.1016/j.jhep.2016.07.038

      Linked Article

      • Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
        Journal of HepatologyVol. 65Issue 3
        • Preview
          Non-alcoholic fatty liver disease (NAFLD) is a clinico-pathological syndrome that ranges from simple steatosis to non-alcoholic steatohepatitis (NASH) with varying amounts of fibrosis, and cirrhosis [1]. NAFLD is becoming the most common cause of chronic liver disease worldwide, affecting up to 30% of the adult population in the United States and Europe [1–3]. Over the past decade, it has become increasingly clear that NAFLD is not only associated with an increased risk of liver-related morbidity or mortality, but also it is a multisystem disease that affects a variety of extra-hepatic organ systems, including the cardiovascular system [3–7].
        • Full-Text
        • PDF
      • Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease
        Journal of HepatologyVol. 65Issue 6
        • Preview
          The evaluation of the nature of the association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular risk has been the topic of a number of reports. There is emerging consensus that NAFLD is positively correlated with increased cardiovascular risk and several groups have indicated that this is independent of known risk factors [1]. The importance of this association is underlined by the observation that cardiovascular disease is a leading cause of death in individuals with NAFLD [2,3].
        • Full-Text
        • PDF
      • Fatty liver is an independent predictor of early carotid atherosclerosis
        Journal of HepatologyVol. 65Issue 1
        • Preview
          Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition seen in patients with obesity, type 2 diabetes, atherogenic dyslipidemia and arterial hypertension. The leading cause of death in patients with NAFLD is cardiovascular mortality, which is not surprising given the high prevalence of the above-mentioned cardiometabolic risk factors [1,2]. However, a large body of data indicates that the fatty and inflamed liver expresses several pro-inflammatory and procoagulant factors, as well as genes involved in accelerated atherogenesis [3,4].
        • Full-Text
        • PDF
      To the Editor:
      We kindly thank Drs. Chimakurthi and Rowe for their thoughtful comments. Waist circumference, an anthropometric measure of abdominal obesity, is known to be associated with cardiovascular (CV) risk, independent of classical risk factors, as suggested by a recent analysis of the Emerging Risk Factors Collaboration [
      • Wormser D.
      • Kaptoge S.
      • Di Angelantonio E.
      • Wood A.M.
      • Pennells L.
      • Thompson A.
      • et al.
      Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies.
      ], but do not significantly add to the prediction accuracy of CV risk models. As waist circumference is a surrogate of hepatic steatosis, the authors suggest that the association between steatosis and increased CV risk only reflects the impact of visceral adiposity on the CV risk.
      Overall, we agree that it is difficult to determine the specific contribution of NAFLD to the increase in CV risk because NAFLD patients have cardiometabolic risk factors that confound this association. Waist circumference is an imperfect clinical marker of visceral adiposity, as it can be influenced by sex, race [
      • Camhi S.M.
      • Bray G.A.
      • Bouchard C.
      • Greenway F.L.
      • Johnson W.D.
      • Newton R.L.
      • et al.
      The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences.
      ,
      • Mongraw-Chaffin M.
      • Golden S.H.
      • Allison M.A.
      • Ding J.
      • Ouyang P.
      • Schreiner P.J.
      • et al.
      The sex and race specific relationship between anthropometry and body fat composition determined from computed tomography: evidence from the multi-ethnic study of atherosclerosis.
      ] and subcutaneous fat. It correlates poorly with visceral fat, when measured by CT-scan, in different ethnic groups [
      • Goncalves F.B.
      • Koek M.
      • Verhagen H.J.
      • Niessen W.J.
      • Poldermans D.
      Body-mass index, abdominal adiposity, and cardiovascular risk.
      ,
      • Ng A.C.
      • Wai D.C.
      • Tai E.S.
      • Ng K.M.
      • Chan L.L.
      Visceral adipose tissue, but not waist circumference is a better measure of metabolic risk in Singaporean Chinese and Indian men.
      ]. Interestingly, in our cohort, waist circumference was an independent predictor of CV risk in patients without steatosis, but not in patients with steatosis (Table 1A, transversal cohort). When adjusting for classical CV risk factors, steatosis was still an independent predictor of CV risk in patients with BMI ⩽25 kg/m2 (beta = 0.051, p = 0.035) or with normal waist (beta = 0.067, p = 0.003). Moreover, in our longitudinal cohort, steatosis, but not waist circumference, predicted the occurrence of carotid plaques during follow-up (Table 1B, longitudinal cohort).
      Table 1Cardiovascular risk factors. (A) Transversal cohort: Independent predictors of C-IMT in patients with and without steatosis. (B) Longitudinal cohort: Independent predictors of the occurrence of carotid plaques in Cox multivariate models.
      Model 2∗ – FLI was replaced by its components.
      An argument in favor of NAFLD as an independent contributor to accelerated atherosclerosis, is the recent demonstration that resolution of NAFLD resulted in regression or a lower progression rate of atherosclerosis. In a sub-analysis of the Welcome trial, Bhatia et al., demonstrated that regression of steatosis (assessed by magnetic resonance spectroscopy) and steatohepatitis (as assessed by serum CK18 fragments) were independently associated with lower carotid intima-media thickness (C-IMT) progression rate, even after adjustment for confounders, including standard CV risk factors, weight changes and specific medication use [
      • Bhatia L.
      • Scorletti E.
      • Curzen N.
      • Clough G.F.
      • Calder P.C.
      • Byrne C.D.
      Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
      ]. Conversely, a recent study of 8020 healthy Korean men has shown that persistent NAFLD (defined by ultrasound) during follow-up was associated with a higher risk of developing carotid plaques even after adjustment for smoking, alcohol, BMI and weight change [
      • Sinn D.H.
      • Cho S.J.
      • Gu S.
      • Seong D.
      • Kang D.
      • Kim H.
      • et al.
      Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis.
      ].
      Our results favor screening for CV disease in patients with NAFLD, a recommendation made by the recent European Association for the Study of the Liver (EASL) clinical practice guidelines. Whether adding NAFLD to existent CV risk scores will improve prediction remains to be proven by long-term, prospective, follow-up studies. A relevant question will then be to determine which of the histological lesions defining NAFLD (steatosis, steatohepatitis or fibrosis) adds significantly to the prediction value of established CV risk models. While hepatic steatosis seems to be associated with early atherosclerosis but not with clinical CV events [
      • Mellinger J.L.
      • Pencina K.M.
      • Massaro J.M.
      • Hoffmann U.
      • Seshadri S.
      • Fox C.S.
      • et al.
      Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham heart study.
      ], liver fibrosis impacts long-term CV outcomes [
      • Perazzo H.
      • Munteanu M.
      • Ngo Y.
      • Lebray P.
      • Seurat N.
      • Rutka F.
      • et al.
      Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
      ,
      • Angulo P.
      • Kleiner D.E.
      • Dam-Larsen S.
      • Adams L.A.
      • Bjornsson E.S.
      • Charatcharoenwitthaya P.
      • et al.
      Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease.
      ]. Since current guidelines do not recommend that patients at risk of CV disease should be screened for NAFLD, these issues deserve to be explored thoroughly in future studies.

      Conflict of interest

      The authors declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

      References

        • Wormser D.
        • Kaptoge S.
        • Di Angelantonio E.
        • Wood A.M.
        • Pennells L.
        • Thompson A.
        • et al.
        Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies.
        Lancet. 2011; 377: 1085-1095
        • Camhi S.M.
        • Bray G.A.
        • Bouchard C.
        • Greenway F.L.
        • Johnson W.D.
        • Newton R.L.
        • et al.
        The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences.
        Obesity. 2011; 19: 402-408
        • Mongraw-Chaffin M.
        • Golden S.H.
        • Allison M.A.
        • Ding J.
        • Ouyang P.
        • Schreiner P.J.
        • et al.
        The sex and race specific relationship between anthropometry and body fat composition determined from computed tomography: evidence from the multi-ethnic study of atherosclerosis.
        PLoS One. 2015; 10e0139559
        • Goncalves F.B.
        • Koek M.
        • Verhagen H.J.
        • Niessen W.J.
        • Poldermans D.
        Body-mass index, abdominal adiposity, and cardiovascular risk.
        Lancet. 2011; 378 ([Author reply 228]): 227
        • Ng A.C.
        • Wai D.C.
        • Tai E.S.
        • Ng K.M.
        • Chan L.L.
        Visceral adipose tissue, but not waist circumference is a better measure of metabolic risk in Singaporean Chinese and Indian men.
        Nutr Diab. 2012; 2e38
        • Bhatia L.
        • Scorletti E.
        • Curzen N.
        • Clough G.F.
        • Calder P.C.
        • Byrne C.D.
        Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
        Atherosclerosis. 2016; 246: 13-20
        • Sinn D.H.
        • Cho S.J.
        • Gu S.
        • Seong D.
        • Kang D.
        • Kim H.
        • et al.
        Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis.
        Gastroenterology. 2016; 151: 481-488
        • Mellinger J.L.
        • Pencina K.M.
        • Massaro J.M.
        • Hoffmann U.
        • Seshadri S.
        • Fox C.S.
        • et al.
        Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham heart study.
        J Hepatol. 2015; 63: 470-476
        • Perazzo H.
        • Munteanu M.
        • Ngo Y.
        • Lebray P.
        • Seurat N.
        • Rutka F.
        • et al.
        Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
        Aliment Pharmacol Ther. 2014; 40: 1081-1093
        • Angulo P.
        • Kleiner D.E.
        • Dam-Larsen S.
        • Adams L.A.
        • Bjornsson E.S.
        • Charatcharoenwitthaya P.
        • et al.
        Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease.
        Gastroenterology. 2015; 149: 389-397